{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:48:50Z","timestamp":1788371330938,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johnson & Johnson Research & Development, LLC., EMEA Medical Affairs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy to treat relapsed\/refractory multiple myeloma is increasing. Studies suggest that effective bridging therapy (BT) prior to anti-BCMA CAR-T therapy can enhance efficacy and safety outcomes. Through qualitative interviews and a consensus workshop, 10 European experts shared their clinical experience regarding optimal BT selection, efficacy, safety and outcomes post\u2013CAR-T, focussing on heavily pretreated patients and emerging BT options, such as bispecific T-cell engagers. Experts agreed that BT should aim to reduce tumour burden and maintain or improve patient performance status, while avoiding treatment-related toxicity that could delay or prevent CAR-T infusion. The balance between treatment duration and achieving an adequate response is important, and patient characteristics are key for BT selection, especially in difficult-to-treat populations. Here, we discuss the unique therapy talquetamab, a GPRC5DxCD3 bispecific antibody, which demonstrates robust efficacy and rapid response rates in clinical trials, and is being considered as a BT option before anti-BCMA CAR-T therapy based on expert experience and real-world data. This consensus, based on clinical experience, aims to provide guidance on BT for healthcare professionals (HCPs) involved in anti-BCMA CAR-T therapy and aid standardisation of care in this rapidly advancing field.<\/jats:p>","DOI":"10.1038\/s41409-026-02905-1","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:17:17Z","timestamp":1778667437000},"page":"785-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Theresa","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine","family":"Agis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Strassl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vu\u010dini\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2905_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2905_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson Jr LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2905_CR3","doi-asserted-by":"crossref","unstructured":"Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, et al. CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. Am Soc Clin Oncol. 2023;7:e6102468.","DOI":"10.1097\/01.HS9.0000967720.61024.68"},{"key":"2905_CR4","unstructured":"EMA. Carvykti (ciltacabtagene autoleucel). Summary of product characteristics. Belgium: Janssen-Cilag International NV; 2024."},{"key":"2905_CR5","unstructured":"EMA. Abecma (idecabtagene vicleucel). Summary of product characteristics, 2022 ed. Dublin: Bristol Myers Squibb; 2025."},{"key":"2905_CR6","unstructured":"FDA. CARVYKTI\u00ae (ciltacabtagene autoleucel) prescribing information. Horsham, PA 19044, USA: Janssen Biotech, Inc; 2025."},{"key":"2905_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"2905_CR8","unstructured":"FDA. ABECMA\u00ae (idecabtagene vicleucel) prescribing information. In: Summit, NJ 07901: Celgene Corporation, a Bristol-Myers Squibb Company; 2025."},{"key":"2905_CR9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2905_CR10","unstructured":"Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update. In: 21st International Myeloma Society Annual Meeting. Rio de Janeiro, Brazil; 2024."},{"key":"2905_CR11","unstructured":"Idecabtagene vicleucel versus standard regimens in patients with triple-class-exposed relapsed and refractory multiple myeloma: updated analysis from KarMMa-3. In 65th ASH Annual Meeting and Exposition. San Diego, California; 2023."},{"key":"2905_CR12","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","volume":"24","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S, et al. Optimizing the CAR T-cell therapy experience in multiple myeloma: Clinical pearls from an expert roundtable. Clin Lymphoma Myeloma. 2024;24:e217\u2013e225.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2905_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39:543\u201354.","journal-title":"Leukemia"},{"key":"2905_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41409-022-01905-1","volume":"58","author":"S Al Hadidi","year":"2023","unstructured":"Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transpl. 2023;58:443\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2905_CR15","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25:e374\u2013e387.","journal-title":"Lancet Oncol"},{"key":"2905_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397.","journal-title":"Blood"},{"key":"2905_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","volume":"6","author":"D Fandrei","year":"2025","unstructured":"Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood Cancer Discov. 2025;6:38\u201354.","journal-title":"Blood Cancer Discov"},{"key":"2905_CR18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.2025029773","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025;146:2063\u201372.","journal-title":"Blood"},{"key":"2905_CR19","unstructured":"Effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. In: 21st International Myeloma Society (IMS) Annual Meeting. Rio de Janeiro, Brazil; 2024."},{"key":"2905_CR20","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S2152-2650(23)01626-9","volume":"23","author":"H Einsele","year":"2023","unstructured":"Einsele H, Rodriguez-Otero P, Arnulf B, Patel K, Manier S, Costa L, et al. P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy. Clin Lymphoma Myeloma Leuk. 2023;23:S37 https:\/\/doi.org\/10.1016\/S2152-2650(23)01626-9.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2905_CR21","doi-asserted-by":"crossref","unstructured":"Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C et al. Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood. 2025;146:1677\u201386.","DOI":"10.1182\/blood.2025028330"},{"key":"2905_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the US Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14:63.","journal-title":"Blood Cancer J"},{"key":"2905_CR23","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Zhou X, Rejeski K, Wagner V, Costello P, Hielscher T, et al. Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025;9:4151\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2024015732.","journal-title":"Blood Adv"},{"key":"2905_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.46989\/001c.116261","volume":"6","author":"ST Bhaskar","year":"2024","unstructured":"Bhaskar ST, Dholaria B, Savani BN, Oluwole O. The evolving role of bridging therapy during CAR-T therapy. Clin Hematol Int. 2024;6:9.","journal-title":"Clin Hematol Int"},{"key":"2905_CR25","doi-asserted-by":"crossref","unstructured":"Kaestner V, Haslam A, Prasad V. Characterization of bridging therapies in clinical trials leading to FDA approval of CAR-T cell therapies. Int J Cancer. 2025;157:1376\u201385.","DOI":"10.1002\/ijc.35473"},{"key":"2905_CR26","unstructured":"Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapse, lenalidomide-refractory multiple myeloma. In: 67th ASH Annual Meeting and Exposition. Orlando, Florida; 2025."},{"key":"2905_CR27","unstructured":"Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma. In: 67th ASH Annual Meeting and Exposition. Orlando, Florida; 2025."},{"key":"2905_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in Multiple Myeloma: current status and future challenges. Blood Cancer J. 2024;14:206. https:\/\/doi.org\/10.1038\/s41408-024-01191-8.","journal-title":"Blood Cancer J"},{"key":"2905_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NW, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","journal-title":"Blood Cancer J"},{"key":"2905_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bjh.19227","volume":"204","author":"S Bal","year":"2024","unstructured":"Bal S, Costa LJ. Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma. Br J Haematol. 2024;204:449\u201354.","journal-title":"Br J Haematol"},{"key":"2905_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jha2.335","volume":"3","author":"ST Bhaskar","year":"2022","unstructured":"Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022;3:39\u201345.","journal-title":"EJHaem"},{"key":"2905_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01049-z","volume":"14","author":"J Richter","year":"2024","unstructured":"Richter J. Like a bridge over troubled water: keeping the myeloma down en route to CAR-T. Blood Cancer J. 2024;14:64.","journal-title":"Blood Cancer J"},{"key":"2905_CR33","unstructured":"EMA Talvey (Talquetamab). Summary of product characteristics. Belgium: Janssen-Cilag International NV; 2023."},{"key":"2905_CR34","unstructured":"FDA Talvey TM (Talquetamab-Tgvs) Prescribing Information. 2023."},{"key":"2905_CR35","doi-asserted-by":"crossref","unstructured":"Rasche L, Schinke CD, Touzeau C, Minnema M, Van De Donk NW, Rodr\u00edguez-Otero P et al. Efficacy and safety from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: analyses at an extended median follow-up. Am Soc Clin Oncol. 2025;43:7528.","DOI":"10.1200\/JCO.2025.43.16_suppl.7528"},{"key":"2905_CR36","unstructured":"P915: long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). Madrid, Spain: European Hematology Association (EHA); 2024."},{"key":"2905_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1182\/blood-2024-202017","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Akhtar OS, Cowan AJ, Richard S, Friend R, Rees MJ, et al. Talquetamab bridging: paving the way to B-cell maturation antigen (BCMA) CAR-T cell therapy in relapsed\/refractory multiple myeloma (RRMM). Blood. 2024;144:931.","journal-title":"Blood"},{"key":"2905_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, et al. Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk. 2024;24:665\u201393.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2905_CR39","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2023.283931","volume":"109","author":"L Liu","year":"2023","unstructured":"Liu L, Krishnan A. Talquetamab in multiple myeloma. Haematologica. 2023;109:718.","journal-title":"Haematologica"},{"key":"2905_CR40","unstructured":"Updated results of talquetamab, a GPRC5D\u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study. In: 65th American Society of Hematology (ASH) Annual Meeting. San Diego, California; 2023."},{"key":"2905_CR41","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"2905_CR42","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","volume":"38","author":"M-V Mateos","year":"2024","unstructured":"Mateos M-V, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma\u20132-year follow-up (final analysis). Leukemia. 2024;38:2554\u201360.","journal-title":"Leukemia"},{"key":"2905_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17:42.","journal-title":"J Hematol Oncol"},{"key":"2905_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"D Dima","year":"2024","unstructured":"Dima D, Abdallah A-O, Davis JA, Awada H, Goel U, Rashid A, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J. 2024;14:90.","journal-title":"Blood Cancer J"},{"key":"2905_CR45","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","volume":"27","author":"SH Manjunath","year":"2021","unstructured":"Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, et al. The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma. Clin Cancer Res. 2021;27:6580\u201390.","journal-title":"Clin Cancer Res"},{"key":"2905_CR46","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R, Gay F, Hungria VT, Dogan A, et al. Multiple myeloma with t (11; 14): unique biology and evolving landscape. Am J Cancer Res. 2022;12:2950.","journal-title":"Am J Cancer Res"},{"key":"2905_CR47","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","volume":"6","author":"J Xu","year":"2017","unstructured":"Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah N, Lehners N, et al. Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation. Oncogenesis. 2017;6:e337\u2013e337.","journal-title":"Oncogenesis"},{"key":"2905_CR48","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","volume":"3","author":"M Andrulis","year":"2013","unstructured":"Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3:862\u20139.","journal-title":"Cancer Discov"},{"key":"2905_CR49","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/cancers13071668","volume":"13","author":"L John","year":"2021","unstructured":"John L, Krauth MT, Podar K, Raab M-S. Pathway-directed therapy in multiple myeloma. Cancers. 2021;13:1668.","journal-title":"Cancers"},{"key":"2905_CR50","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/j.clml.2014.06.004","volume":"14","author":"J Sharman","year":"2014","unstructured":"Sharman J, Chmielecki J, Morosini D, Palmer G, Ross J, Stephens P, et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E\u2013mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14:e161\u2013e163.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2905_CR51","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","volume":"105","author":"PA Egan","year":"2020","unstructured":"Egan PA, Elder PT, Deighan WI, O\u2019Connor SJ, Alexander HD. Multiple myeloma with central nervous system relapse. Haematologica. 2020;105:1780.","journal-title":"Haematologica"},{"key":"2905_CR52","doi-asserted-by":"publisher","first-page":"934240","DOI":"10.3389\/fonc.2022.934240","volume":"12","author":"V Sammartano","year":"2022","unstructured":"Sammartano V, Cerase A, Venanzi V, Mazzei MA, Vangone BE, Gentili F, et al. Central nervous system myeloma and unusual extramedullary localizations: real life practical guidance. Front Oncol. 2022;12:934240.","journal-title":"Front Oncol"},{"key":"2905_CR53","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","volume":"9","author":"MR Gaballa","year":"2025","unstructured":"Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, et al. BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv. 2025;9:1171\u201380.","journal-title":"Blood Adv"},{"key":"2905_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00277-022-05027-y","volume":"102","author":"S Ghandili","year":"2023","unstructured":"Ghandili S, Alihodzic D, Wiessner C, Bokemeyer C, Weisel K, Leypoldt LB. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed\/refractory multiple myeloma: a single-center experience. Ann Hematol. 2023;102:117\u201324. https:\/\/doi.org\/10.1007\/s00277-022-05027-y.","journal-title":"Ann Hematol"},{"key":"2905_CR55","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1080\/10428194.2021.1907373","volume":"62","author":"T Huynh","year":"2021","unstructured":"Huynh T, Corre E, Lemonnier MP, Dulery R, Marjanovic Z, Jaff N, et al. Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leuk Lymphoma. 2021;62:2235\u201341. https:\/\/doi.org\/10.1080\/10428194.2021.1907373.","journal-title":"Leuk Lymphoma"},{"key":"2905_CR56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16:88.","journal-title":"J Hematol Oncol"},{"key":"2905_CR57","doi-asserted-by":"publisher","unstructured":"Van de Donk N, Moreau P, San Miguel JF, Mateos MV. Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: practical guidance from the European Myeloma Network. HemaSphere. 2025;9. https:\/\/doi.org\/10.1002\/hem3.70260","DOI":"10.1002\/hem3.70260"},{"key":"2905_CR58","first-page":"4360926","volume":"2020","author":"RD Parrondo","year":"2020","unstructured":"Parrondo RD, Roy V, Sher T, Alegria V, Chanan-Khan AA, Ailawadhi S. Use of KRD-PACE as salvage therapy in aggressive, relapsed\/bortezomib-refractory extramedullary multiple myeloma: a report of two cases and literature review. Case Rep Hematol. 2020;2020:4360926.","journal-title":"Case Rep Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02905-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02905-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02905-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:59:27Z","timestamp":1783601967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02905-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2905"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02905-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LR: has received research support from BMS, has served in advisory boards for Amgen, BMS, Roche, Johnson & Johnson, Sanofi, GSK, and Pfizer, and received honoraria from Amgen, BMS, Roche, Johnson & Johnson, Sanofi, GSK, Pfizer, and Takeda. MTK: consultant for and has served in advisory boards for: Amgen, Celgene, Novartis, BMS, J&J, Sanofi, GSK, Takeda, Pfizer, Oncopeptides, and Stemline. HA: has received honoraria from Amgen, BMS, GSK, Johnson & Johnson, Pfizer, and Takeda, and has received research support from Johnson & Johnson. CR: has served in advisory boards for BMS\/Celgene, BeiGene, Roche, Johnson & Johnson, Sanofi, GSK, and Pfizer, and received honoraria from BMS\/Celgene, Roche, Johnson & Johnson, Sanofi, Pfizer, and Stemline. IS: has served in advisory boards for: Amgen, BMS, GSK, Johnson & Johnson, Pfizer, and Sanofi, and received honoraria from Abbvie, Amgen, BMS, Gilead, GSK, Johnson & Johnson, Pfizer, Sanofi, Stemline, and Takeda. RT: has served in advisory boards for AbbVie, Amgen, BMS, Gilead, GSK, Johnson & Johnson, Oncopeptides, Sanofi, Stemline and Takeda, received research support from Johnson & Johnson, received travel grants from Amgen and Johnson & Johnson and received honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, GSK, Johnson & Johnson, Pfizer and Stemline. VV: has received research support from Amgen, has served on advisory boards for Amgen, BMS\/Celgene, Johnson & Johnson, Gilead\/Kite, AstraZeneca, Abbvie and received honoraria from Johnson & Johnson, Gilead\/Kite, Abbvie, AstraZeneca, Elli Lilly, and Roche. KW: has received research support from Abbvie, Amgen, BMS, Johnson & Johnson, GSK, and Sanofi, received honoraria from Abbvie, Adaptive Biotech, Amgen, Astra Zeneca, BeiGene, BMS, Johnson & Johnson, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline, Takeda, has received consulting fees from Abbvie, Adaptive Biotech, Amgen, Astra Zeneca, BeiGene, BMS, CellCentric, Johnson & Johnson, GSK, Karyopharm, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline, Takeda WW: has received research support from Amgen, Astra-Zeneca, BMS\/Celgene, Johnson & Johnson, Novartis, Pfizer, Roche, Sanofi, and Takeda, has participated in steering and safety committees, advisory boards and given lectures for Amgen, Abbvie, Astra Zeneca, BeiGene, BMS\/Celgene, Blueprint, CSL-Behring, Dayton, DSMM, EUSA Pharma, Gilead, GSK, IQVIA, Incyte, Johnson & Johnson, Kite, Merck, Myelom- and Lymphomselbsthilfe \u00d6sterreich, MedMedia, Morphosys, Novartis, Onconovum, Pharma&, Pfizer, Roche, Sandoz, Sanofi, Stemline-Menarini, Takeda MSR: has received research funding from BMS, Johnson & Johnson, Sanofi, and Heidelberg Pharma, has received honoraria from BMS, Johnson & Johnson, AbbVie, Sanofi, Oncopeptides, has performed a consulting or advisory role for BMS, Amgen, GSK, Johnson & Johnson, Sanofi, Pfizer, AbbVie and has received travel funding from BMS, Amgen, Johnson & Johnson, Oncopeptides","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}